Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05065294 · ClinicalTrials.gov registry record · Phase 2
Psilocybin Therapy for Depression in Bipolar II Disorder
A Phase 2 study of Bipolar II Disorder, sponsored by University of California, San Francisco.
- Active
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT05065294 is a Phase 2 study of Bipolar II Disorder that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 14 participants, below the 87-participant average among 13 other Bipolar II Disorder trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05065294, a Phase 2 study of Bipolar II Disorder, is active but no longer recruiting, sponsored by University of California, San Francisco.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy in people with Bipolar II Disorder.
Conditions Studied
Interventions
- DRUG Psilocybin therapy
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2022-01-28 |
| Est. Completion | 2025-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05065294
The ClinicalTrials.gov registry entry for NCT05065294 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 87-participant average among 13 other Bipolar II Disorder trials with a reported enrollment target (84% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bipolar II Disorder appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin therapy is the first listed.
NCT05065294 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05065294 about?
NCT05065294 is a clinical study titled "Psilocybin Therapy for Depression in Bipolar II Disorder". The purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy in people with Bipolar II Disorder.
What is the current status of trial NCT05065294?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2022-01-28. Estimated completion is 2025-07.
What conditions does trial NCT05065294 study?
This clinical trial studies the following conditions: Bipolar II Disorder.
What interventions are being tested in trial NCT05065294?
The interventions under investigation include: Psilocybin therapy (DRUG).
Who is sponsoring clinical trial NCT05065294?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05065294 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar II Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders
RECRUITING · Phase 2
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
RECRUITING · Phase 2
-
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality
RECRUITING · Phase 2
-
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Treating Smokers With Mental Illness
COMPLETED · Phase 2
-
Psychotherapy for Bipolar II Depression, Pilot Study, Phase II
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.